These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30995725)

  • 1. Insights into the Molecular Mechanisms of Eg5 Inhibition by (+)-Morelloflavone.
    Ogunwa TH; Laudadio E; Galeazzi R; Miyanishi T
    Pharmaceuticals (Basel); 2019 Apr; 12(2):. PubMed ID: 30995725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Morelloflavone as a novel inhibitor of mitotic kinesin Eg5.
    Ogunwa TH; Taii K; Sadakane K; Kawata Y; Maruta S; Miyanishi T
    J Biochem; 2019 Aug; 166(2):129-137. PubMed ID: 30785183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kolaflavanone, a biflavonoid derived from medicinal plant Garcinia, is an inhibitor of mitotic kinesin Eg5.
    Alrazi IMD; Ogunwa TH; Kolawole AO; Elekofehinti OO; Omotuyi OI; Miyanishi T; Maruta S
    J Biochem; 2021 Dec; 170(5):611-622. PubMed ID: 34264310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
    Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
    Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the human kinesin Eg5 that confer resistance to monastrol and S-trityl-L-cysteine in tumor derived cell lines.
    Tcherniuk S; van Lis R; Kozielski F; Skoufias DA
    Biochem Pharmacol; 2010 Mar; 79(6):864-72. PubMed ID: 19896928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eg5 Inhibitors Have Contrasting Effects on Microtubule Stability and Metaphase Spindle Integrity.
    Chen GY; Kang YJ; Gayek AS; Youyen W; Tüzel E; Ohi R; Hancock WO
    ACS Chem Biol; 2017 Apr; 12(4):1038-1046. PubMed ID: 28165699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug resistance dependent on allostery: A P-loop rigor Eg5 mutant exhibits resistance to allosteric inhibition by STLC.
    Indorato RL; DeBonis S; Garcia-Saez I; Skoufias DA
    Front Oncol; 2022; 12():965455. PubMed ID: 36313676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
    Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
    J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of new allosteric inhibition in Kinesin spindle protein Eg5.
    Yokoyama H; Sawada J; Katoh S; Matsuno K; Ogo N; Ishikawa Y; Hashimoto H; Fujii S; Asai A
    ACS Chem Biol; 2015 Apr; 10(4):1128-36. PubMed ID: 25622007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
    Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
    Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MD simulation-based screening approach identified tolvaptan as a potential inhibitor of Eg5.
    Sebastian J; Raghav D; Rathinasamy K
    Mol Divers; 2023 Jun; 27(3):1203-1221. PubMed ID: 35789974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and Thermodynamic Basis of the Enhanced Interaction between Kinesin Spindle Protein Eg5 and STLC-type Inhibitors.
    Yokoyama H; Sawada JI; Sato K; Ogo N; Kamei N; Ishikawa Y; Hara K; Asai A; Hashimoto H
    ACS Omega; 2018 Sep; 3(9):12284-12294. PubMed ID: 31459302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic monastrol derivatives as adjective inhibitors of drug-resistant Eg5: a molecular dynamics perspective.
    Shahabipour S; Shamkhali AN; Razzaghi-Asl N
    J Biomol Struct Dyn; 2024 Mar; ():1-14. PubMed ID: 38450658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.
    Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S
    Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the interaction of the Eg5 Loop5 with the nucleotide site.
    Harrington TD; Naber N; Larson AG; Cooke R; Rice SE; Pate E
    J Theor Biol; 2011 Nov; 289():107-15. PubMed ID: 21872609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding patterns of inhibitors to different pockets of kinesin Eg5.
    Jia N; Zhang B; Huo Z; Qin J; Ji Q; Geng Y
    Arch Biochem Biophys; 2024 Jun; 756():109998. PubMed ID: 38641233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The conserved L5 loop establishes the pre-powerstroke conformation of the Kinesin-5 motor, eg5.
    Larson AG; Naber N; Cooke R; Pate E; Rice SE
    Biophys J; 2010 Jun; 98(11):2619-27. PubMed ID: 20513406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structure of the ternary Eg5-ADP-ispinesib complex.
    Talapatra SK; Schüttelkopf AW; Kozielski F
    Acta Crystallogr D Biol Crystallogr; 2012 Oct; 68(Pt 10):1311-9. PubMed ID: 22993085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATPase mechanism of Eg5 in the absence of microtubules: insight into microtubule activation and allosteric inhibition by monastrol.
    Cochran JC; Gilbert SP
    Biochemistry; 2005 Dec; 44(50):16633-48. PubMed ID: 16342954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex.
    Kaan HY; Ulaganathan V; Hackney DD; Kozielski F
    Biochem J; 2009 Dec; 425(1):55-60. PubMed ID: 19793049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.